Overview
Join a panel of world-renowned experts for an interactive and practical exploration of gene therapies for hemophilia. Topics will include recent updates on long-term efficacy and safety data for approved and emerging agents; understanding the key similarities and differences between gene therapies for hemophilia A and hemophilia B in areas such as outcomes, eligibility criteria, and post-infusion monitoring requirements; and best practices for identification of appropriate candidates and successful shared decision-making conversations. A detailed audience survey at the opening of the program will allow faculty to tailor their final discussion and Q&A to the essential practical information attendees need to be able to implement or expand the hemophilia gene therapy program at their institutions.
Speakers
Steven W. Pipe, MD
Professor of Pediatrics and Pathology
Pediatric Medical Director, Hemophilia and Coagulation Disorders Program
Director of Special Coagulation Laboratory
University of Michigan
Ann Arbor, Michigan
Doris V. Quon, MD, PhD
Medical Director
Hemophilia Treatment Center
Luskin Orthopaedic Institute for Children
Los Angeles, California
Amy L. Dunn, MD
Professor of Pediatrics
Director of Pediatric Hematology
Hemophilia Treatment Center
Nationwide Children’s Hospital
The Ohio State University
College of Medicine
Columbus, Ohio
Agenda
3:30 ᴘᴍ
Welcome and Introduction
3:35 ᴘᴍ
Interactive Audience Survey: Knowledge of and Experience With Hemophilia Gene Therapies
3:45 ᴘᴍ
Understanding the Gene Therapy Process: From Patient Selection to Post-Infusion Monitoring
4:00 ᴘᴍ
Comparing Gene Therapy Outcomes: Efficacy and Safety in Hemophilia A and Hemophilia B
4:20 ᴘᴍ
Roundtable Discussion: Practical Considerations in Implementation of Hemophilia Gene Therapy
4:45 ᴘᴍ
Closing Remarks and Audience Q&A
333 W Harbor Drive,
Room: Grand Ballroom 8-9,
San Diego, California, 92101
San Diego, California, 92101
Program Information
Accreditation Statement
In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
[bold]For Physicians[/bold][break]
Medscape, LLC designates this live activity for a maximum of 1.5 [italic]AMA PRA Category 1 Credits[/italic]™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
[break][break]
[bold]For Nurses[/bold][break]
Awarded 1.50 contact hour(s) of nursing continuing professional development for RNs and APNs.
[break][break]
[bold]For Pharmacists[/bold][break]
Medscape designates this continuing education activity for 1.50 contact hour(s) (0.150 CEUs) (Universal Activity Number: JA0007105-0000-24-232-L01-P).
Learning Objectives
Upon completion of this activity, participants will:
Have increased knowledge regarding the[list][item]Clinical and practical evidence surrounding gene therapies for hemophilia[item]Differences in gene therapies for hemophilia A and hemophilia B[/list]Have greater competence related to[list][item]Identifying eligible candidates for gene therapies for hemophilia[item]Monitoring patients with hemophilia who receive gene therapies[/list]
Demonstrate greater confidence in their ability to[list][item]
Counsel patients and colleagues about gene therapies for hemophilia[/list]
Goal Statement
The goal of this activity is for learners to be better able to recognize the key differences in gene therapies for hemophilia A compared with hemophilia B, and to leverage evolving data about gene therapies for hemophilia to better care for patients.
Target Audience
This activity is intended for hematologists, emergency medicine physicians, nurses, nurse practitioners, physician assistants, and other members of the hemophilia care team.
A Friday Satellite Symposium on Hematology, preceding the 66th ASH Annual Meeting and Exposition.
Supported by an independent educational grant from CSL Behring.